Tracy Walker from Managed Healthcare Executive talks with Precision for Value’s Jeremy Schafer regarding Kymriah, the first gene therapy approved for cancer treatment. (more…)
PHE Scientific Advisor Anupam Jena, coauthor of a new study on preeclampsia in the September issue of American Journal of Obstetrics & Gynecology, discussed the study’s findings and the growing economic impact of the condition with the Orlando Sentinel’s Amelia Cheatham. (more…)
In a new article appearing in the latest MM&M, Precision for Value EVP and Managing Partner Kelly Wilder shares her perspective on the challenges of marketing new heart drugs. (more…)
Precision for Value is pleased to announce it has again been named to MM&M magazine’s Top 100 Healthcare Agencies. In fact, this is the third straight year that Precision for Value has made the prestigious list, dating to the introduction of the PFV brand in 2015. (more…)
After spending millions on R&D just to get a product to market—and millions more promoting it—there’s nothing worse than when a launch falls flat. In a just-published panorama on PM360, Precision for Value’s Kelly Wilder identifies several critical mistakes that pharma companies make that can reduce the perceived value of a product in the marketplace. (more…)
In this month’s Drug Topics, correspondent Kathleen Gannon Longo talks with Precision for Value’s Jeremy Schafer on the potentially tremendous impact that value assessments will have on future patient reimbursement decisions. (more…)
During the recent ISPOR conference, Ross Maclean, Precision Health Economics’ SVP, Head of Medical, sat down to talk with Med Ad News’ Christiane Truelove on new opportunities for payer access in light of new FDA draft guidance around section 3037 of the 21st Century Cures Act. (more…)
In the latest edition of Managed Healthcare Executive, Precision for Value’s Kellie Rademacher provides her perspective on the magazine’s second annual managed care pharmacy survey. (more…)
In a new guest column appearing in the latest edition of Clinical Leader, Precision for Value’s Jeremy Schafer argues for the inclusion of value measurements into oncology trials, outlining the potential end points as well as the significant rewards that can be gained after product launch due to the enhanced value proposition. (more…)
For the second year in a row, Precision Health Economics Senior Research Economist Jason Shafrin’s blog, “Healthcare Economist,” has been named by Intelligent Economist to their list of Top 100 Economics Blogs (worldwide). (more…)